<DOC>
	<DOCNO>NCT00068744</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , mitomycin , fluorouracil , cisplatin , use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . It yet know whether radiation therapy mitomycin effective combine fluorouracil cisplatin treat anal cancer . PURPOSE : This randomized phase II/III trial study well give radiation therapy mitomycin together fluorouracil work compare radiation therapy , mitomycin , cisplatin treat patient locally advanced anal cancer .</brief_summary>
	<brief_title>Radiation Therapy , Mitomycin , Either Fluorouracil Cisplatin Treating Patients With Locally Advanced Anal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Phase II - Primary - Compare early clinical response ( tumor response 8 week ) patient locally advanced anal cancer treat radiotherapy mitomycin cisplatin v mitomycin fluorouracil . - Secondary - Compare feasibility regimens patient . - Compare acute toxicity regimens patient . - Compare patient compliance regimen . Phase III - Primary - Compare event-free survival patient treat regimen . - Secondary - Compare colostomy-free , disease-free , overall survival patient treat regimen . - Compare locoregional control patient treat regimen . - Compare late toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , T stage ( T2 vs T3 v T4 ) , nodal status ( N0 v N+ ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo radiotherapy daily 5 day week week 1-4 , 7-8 , 3 day week 9 ( total 33 fraction ) . Patients concurrently receive fluorouracil IV continuously day 1-26 43-59 mitomycin IV 15 minute day 1 43 . - Arm II : Patients receive radiotherapy mitomycin arm I cisplatin IV 1 hour day 1 , 8 , 15 , 22 , 43 , 50 , 57 . In arm , treatment continue absence disease progression unacceptable toxicity . Quality life assess baseline , week 12 26 , every 6 month 2 year . Patients follow every 2 week 8 week , week 26 , every 6 month thereafter . PROJECTED ACCRUAL : A total 678 patient ( 80 [ 40 per treatment arm ] phase II 598 [ 299 per treatment arm ] phase III ) accrue study within 2-5 year .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell anal carcinoma Keratinizing nonkeratinizing The following stage eligible : T2 , N0 , M0 maximum tumor diameter least 4 cm T3T4 , N0 , M0 Any T , N1N3 , M0 Tumor locate anal canal OR anal margin infiltrate anal canal No primary adenocarcinoma anus Measurable disease PATIENT CHARACTERISTICS : Age 18 75 Performance status WHO 01 Life expectancy Not specify Hematopoietic Granulocyte count great 2,000/mm^3 Platelet count great 100,000/mm^3 Hepatic Not specify Renal Creatinine le 1.4 mg/dL Cardiovascular No grade I angina pectoris clinical symptom within past 3 month No grade IIIV angina pectoris within past 3 month No stage II great distal arteritis Other Not pregnant nursing Fertile patient must use effective contraception No prior malignancy except adequately treat basal cell skin cancer carcinoma situ cervix No psychological , familial , sociological , geographical condition would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No concurrent radiotherapy Surgery No prior colostomy Other No prior treatment anal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>squamous cell carcinoma anus</keyword>
	<keyword>stage II anal cancer</keyword>
	<keyword>stage IIIA anal cancer</keyword>
	<keyword>stage IIIB anal cancer</keyword>
</DOC>